RACGP response to Advisory Committee on Medicines Scheduling - Cytisine


Date: February 2024

The RACGP recommends the scheduling of cytisine for the treatment of nicotine dependence.  There is moderately certain evidence supporting the efficacy of cytisine for smoking cessation. It may cause mild gastrointestinal symptoms, however it has a very low risk of serious adverse effects. It is now approved for use in the UK by the Medicines and Healthcare Products Regulatory Agency and is subsidies by the National Health Service

 

Read the submission

RACGP response to Advisory Committee on Medicines Scheduling - Cytisine (PDF)

Advertising

Advertising